Search results for "Intravenous"

showing 10 items of 390 documents

Patients' and relatives' perceptions about intravenous and subcutaneous hydration.

2005

Hydration during palliative care is a controversial topic. Most of the arguments are based on anedoctal reports that have not been substantiated with scientific data. Given that the choice is problematic from a clinical perspective, preferences of patients and family should dictate whether intravenous fluids are administered. The aim of this study was to evaluate patient and family perceptions about hydration and two modes of providing hydration. Fifty-four consecutive patients admitted to an acute pain relief and palliative care unit who required hydration completed a questionnaire regarding their perceptions on hydration and modes of hydration. Similarly, the principal family carer was ch…

AdultMalemedicine.medical_specialtyPalliative carePatientsmedia_common.quotation_subjectInjections SubcutaneousMEDLINEadvanced cancer patientsPatient satisfactionPerceptionmedicineSubcutaneous HydrationHumansFamilyIntensive care medicineFamily carerInfusions Intravenousintravenous and subcutaneous hydrationGeneral Nursingmedia_commonAgedAged 80 and overbusiness.industryPalliative CareMiddle AgedSubcutaneous routeAnesthesiology and Pain MedicinePatient SatisfactionPatients' and relatives' perceptionFluid TherapyFemaleNeurology (clinical)businessIntravenous routeJournal of pain and symptom management
researchProduct

PANCREATIC CARCINOMA VERSUS CHRONIC FOCAL PANCREATITIS: CONTRAST-ENHANCED POWER DOPPLER ULTRASONOGRAPHY FINDINGS

2005

Background: We assessed the potential usefulness of contrast-enhanced power Doppler ultrasonography (US) for differentiating pancreatic carcinoma from chronic focal pancreatitis. Methods: Twenty-six consecutive patients with ductal carcinoma (n=16) and chronic focal pancreatitis (n=10) underwent power Doppler US examinations before and after intravenous injection of an air-based contrast agent (Levovist, Schering, Berlin, Germany). Final diagnosis was obtained by surgery in all patients. The following parameters before and after intravenous administration of contrast agent were evaluated for each lesion: number, morphology and course of the vessels within the lesion and time to maximum dete…

AdultMalemedicine.medical_specialtyPancreatic diseasechronic focal pancreatitiUrologyContrast MediaAdenocarcinomaDiagnosis DifferentialLesionPolysaccharidesInternal medicinemedicineCarcinomaHumansRadiology Nuclear Medicine and imagingAgedRetrospective Studiespower Doppler ultrasonographyRadiological and Ultrasound Technologypancreatic carcinomabusiness.industryultrasoundUltrasoundGastroenterologyUltrasonography DopplerGeneral MedicineMiddle AgedDuctal carcinomaHepatologymedicine.diseasePancreatic NeoplasmsPancreatitisChronic DiseaseInjections IntravenousPancreatitisFemaleRadiologymedicine.symptombusinessBlood Flow Velocitycontrast-enhanced ultrasoundContrast-enhanced ultrasound
researchProduct

Heterogeneous delayed enhancement of hepatic parenchyma after intravenous infusion of sonographic contrast agent: a new hypothesis

2007

Purpose. The aim of this paper was to report a heterogeneous latephase hepatic enhancement pattern observed after administration of a sonographic contrast agent and to present an aetiological hypothesis for the phenomenon. Materials and methods. A total of 1,729 (1,012 women and 717 men; age range 28–82; mean age 51) patients underwent contrastenhanced sonography of the liver. The examination was performed with a low mechanical index (MI <0.09) after injection of sulphur-hexafluoride-filled microbubbles, using different fonographic equipment and different contrast-specific algorithms. Results. Heterogeneous delayed liver enhancement was observed in six patients in the late phase (180 s), wi…

AdultMalemedicine.medical_specialtyPathologyTime FactorsSulfur HexafluorideContrast MediaHepatic ArteryMesenteric VeinsmedicineHumansRadiology Nuclear Medicine and imagingSuperior mesenteric veinInfusions IntravenousUltrasound Microbubbles LiverPhospholipidsAgedUltrasonographyNeuroradiologyAged 80 and overMicrobubblesmedicine.diagnostic_testPortal Veinbusiness.industryUltrasoundEchogenicityInterventional radiologyGeneral MedicineMiddle AgedImage EnhancementPeripheralLiverMicrobubblesFemaleRadiologySettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessMechanical indexLiver CirculationLa radiologia medica
researchProduct

Relationship between preoperative anxiety and postoperative satisfaction in dental implant surgery with intravenous conscious sedation

2008

Purpose: To study if patient preoperative anxiety is related to age and gender and to compare preoperative anxiety with postoperative patient and surgeon satisfaction in dental implant surgery under intravenous conscious sedation. Materials and Methods: Dental implants were placed in 102 patients under local anesthesia and intravenous conscious sedation. The procedures were performed with or without dental extractions, and with or without bone regeneration. Anxiety was evaluated using Corah?s Dental Anxiety Scale and levels of surgeon and patient satisfaction were evaluated on an adapted scale. Results: Low preoperative anxiety was observed in 27.8% of patients, moderate in 50%, and high in…

AdultMalemedicine.medical_specialtyPatient anxietySedationConscious SedationAnxietyJob SatisfactionDental implant surgeryPatient satisfactionSurveys and QuestionnairesmedicineHumansHypnotics and SedativesLocal anesthesiaBone regenerationGeneral DentistryDental Implantsbusiness.industry:CIENCIAS MÉDICAS [UNESCO]SurgeryOtorhinolaryngologyPatient SatisfactionAnesthesiaInjections IntravenousUNESCO::CIENCIAS MÉDICASAnxietyFemaleSurgeryJob satisfactionmedicine.symptombusinessAnesthesia LocalMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Phase 1B Study of the Pharmacokinetics and Safety of Posaconazole Intravenous Solution in Patients at Risk for Invasive Fungal Disease

2014

ABSTRACT This was a phase 1B, dose-ranging, multicenter, pharmacokinetics, and safety study of cyclodextrin-based posaconazole intravenous (i.v.) solution administered through a central line to subjects at high risk for invasive fungal disease (part 1 of a 2-part study [phase 1B/3]). Initially, the safety and tolerability of single-dose posaconazole i.v. 200 mg ( n = 10) were compared with those of a placebo ( n = 11). Subsequently, 2 doses were evaluated, posaconazole i.v. 200 mg once daily (q.d.) ( n = 21) and 300 mg q.d. ( n = 24). The subjects received twice-daily (b.i.d.) posaconazole i.v. on day 1, followed by 13 days of posaconazole i.v. q.d., then 14 days of posaconazole oral suspen…

AdultMalemedicine.medical_specialtyPosaconazoleAntifungal AgentsPhases of clinical researchPharmacologyPlaceboGastroenterologyCohort StudiesPharmacokineticsInternal medicinemedicineHumansPharmacology (medical)DosingAgedPharmacologyDose-Response Relationship Drugbusiness.industryMiddle AgedTriazolesPharmaceutical SolutionsDose–response relationshipInfectious DiseasesMycosesTolerabilityInjections IntravenousCohortFemalebusinessmedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct

The Effects of Prostaglandin E-1 in Patients with Intermittent Claudication

2006

Aim of the study is to evaluate the effects of Prostaglandin E-1 (PGE-1) in patients with peripheral arterial disease (PAD) at the 2nd b stage Fontaines classification. The study, controlled, single blinded, enrolled 123 patients with intermittent claudication that were randomised in two groups; the first group received a treatment with PGE-1 while the second one received a pentoxifylline-buflomedil association by venous infusion. We evaluated: Pain Free Walking Distance (PFWD), Maximum Walking Distance (MWD), Rest Flow (RF), Peak Flow (PF), Basal (BVR) and Minimal Vascular Resistance (MVR) with a strain gauge plethysmograph, Resting Flow (RF), Peak Flow (PF), time to reach the Peak Flow (t…

AdultMalemedicine.medical_specialtyPyrrolidinesVasodilator AgentsProstaglandinHemodynamicsWalkingSeverity of Illness IndexMicrocirculationchemistry.chemical_compoundInternal medicineLaser-Doppler FlowmetrymedicineHumansPlethysmographAlprostadilPentoxifyllineInfusions IntravenousAgedPharmacologybusiness.industryHematologyGeneral MedicineIntermittent ClaudicationMiddle AgedLaser Doppler velocimetryIntermittent claudicationSurgeryPeripheralPlethysmographyDrug CombinationsTreatment Outcomemedicine.anatomical_structurechemistryRegional Blood FlowExercise TestVascular resistanceCardiologyMolecular MedicineFemaleVascular Resistancemedicine.symptomCardiology and Cardiovascular MedicinebusinessCardiovascular &amp; Hematological Disorders-Drug Targets
researchProduct

Oral high-dose sucrosomial iron vs intravenous iron in sideropenic anemia patients intolerant/refractory to iron sulfate: a multicentric randomized s…

2020

AbstractIron deficiency anemia is among the most frequent causes of disability. Intravenous iron is the quickest way to correct iron deficiency, bypassing the bottleneck of iron intestinal absorption, the only true mechanism of iron balance regulation in human body. Intravenous iron administration is suggested in patients who are refractory/intolerant to oral iron sulfate. However, the intravenous way of iron administration requires several precautions; as the in-hospital administration requires a resuscitation service, as imposed in Europe by the European Medicine Agency, it is very expensive and negatively affects patient’s perceived quality of life. A new oral iron formulation, Sucrosomi…

AdultMalemedicine.medical_specialtyResuscitationIntravenous sodium ferrigluconateAnemiaCost-Benefit AnalysisHigh dosesAdministration OralHigh dose030204 cardiovascular system & hematologyGastroenterologyFerric CompoundsIntestinal absorption03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRefractoryInternal medicineOral Sucrosomial ironMedicineHumans030212 general & internal medicineFerrous CompoundsProspective StudiesAgedAged 80 and overHematologyAnemia Iron-Deficiencybusiness.industryHematologyGeneral MedicineIron deficiencyMiddle Agedmedicine.diseaseIron sulfatechemistryIron-deficiency anemiaIron deficiency anemiaHematinicsAdministration IntravenousFemaleOriginal ArticleRefractoriness/intolerance to oral iron sulfatebusiness
researchProduct

Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol

2006

Objectives: to evaluate the clinical efficacy and the effects on the quality of life of Iloprost, a prostacyclin analogue, used, according to a new protocol, in patients with Raynaud’s phenomenon secondary to Systemic Sclerosis. Methods: in this randomized study we treated 30 patients with Iloprost given by intravenous infusion, at progressively increasing doses (starting from 0.5 ng/Kg/min up 2 ng/Kg/min) over a period of 6 hours a day for ten days in two consecutive weeks, with repeated cycles at regular intervals of three months for 18 months. The results were compared with those obtained in 30 other patients, who had received the same drug but with different posologic schemes. Results: …

AdultMalemedicine.medical_specialtyTime FactorsVasodilator AgentsSeverity of Illness IndexDrug Administration ScheduleSclerodermalaw.inventionRheumatologyRandomized controlled trialQuality of lifelawSeverity of illnessmedicineHumansPharmacology (medical)IloprostProspective StudiesDosingInfusions IntravenousProspective cohort studySystemic Sclerosis Raynaud's phenomenon Iloprost Quality of lifeScleroderma SystemicDose-Response Relationship DrugVascular diseasebusiness.industryRaynaud DiseaseMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeAnesthesiaQuality of LifeFemalebusinessIloprostmedicine.drugRheumatology
researchProduct

Intratympanic Dexamethasone/Hyaluronic Acid Mix as an Adjunct to Intravenous Steroid and Vasoactive Treatment in Patients With Severe Idiopathic Sudd…

2011

To evaluate differences in effectiveness (hearing recovery rates) between idiopathic sudden sensorineural hearing loss (ISSNHL) patients treated with intravenous therapy alone and patients treated with a combination of intravenous and intratympanic therapy.Retrospective case review.Tertiary referral hospital center.Ninety-four patients with moderate ISSNHL treated with an intravenous steroid and vasoactive regimen (duration of therapy, 9 ± 2.76 d) and 76 patients with severe ISSNHL treated with a combination regimen of intravenous and intratympanic therapy (duration of therapy, 10 ± 2.71 d) were reviewed. In the latter patients' group, a series of 3 intratympanic injections of a dexamethaso…

AdultMalemedicine.medical_specialtyTympanic MembraneHearing Loss Sensorineuralmedicine.medical_treatmentIntratympanic dexamethasoneDexamethasoneInjectionsSteroidchemistry.chemical_compoundVasoactiveInternal medicineHyaluronic acidotorhinolaryngologic diseasesmedicineHumansIn patientHyaluronic AcidGlucocorticoidsRetrospective Studiesbusiness.industryHearing Loss SuddenSensory SystemsHearing recoveryTreatment OutcomeEndocrinologyOtorhinolaryngologychemistryIntravenous therapyAnesthesiaSudden sensorineural hearing lossInjections IntravenousAudiometry Pure-ToneFemaleSteroidsNeurology (clinical)businessOtology &amp; Neurotology
researchProduct

Pharmacokinetics of atenolol in relation to renal function

1981

The plasma levels and urinary excretion of carteolol and its main metabolites 8-hydroxycarteolol and carteolol glucuronide were investigated in 6 healthy subjects and 9 patients with varying degrees of renal impairment following a single oral dose of 30 mg carteolol hydrochloride. In healthy subjects the half-life of carteolol was 7.1 h. 63% of the administered dose was recovered unchanged in urine, and in all 84% was excreted by the kidneys. The renal clearance of carteolol was 255 ml/min. In chronic renal failure (CRF) the terminal half-life was increased to a maximum of 41 h. Both the elimination rate constant and renal clearance were closely related to the creatinine clearance. In CRF t…

AdultMalemedicine.medical_specialtyUrologyAdministration OralRenal functionCarteolol HydrochloridePropanolamineschemistry.chemical_compoundPharmacokineticsElimination rate constantRenal DialysisInternal medicinemedicineHumansPharmacology (medical)CarteololAgedPharmacologyKidneyCreatinineMaintenance dosebusiness.industryGeneral MedicineMiddle AgedKineticsEndocrinologymedicine.anatomical_structureAtenololchemistryInjections IntravenousFemaleKidney DiseasesbusinessGlomerular Filtration Ratemedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct